TMDX — Stock Film
STOCK FILMSCENE 1/11TMDX · $76.00
Stock Expert AI presents
TMDX
TransMedics Group, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
TransMedics Group, Inc. A quick introduction.

On the stock market since 2019, it operates in the world of health and science. It has 898 employees. Now — the numbers.

on the stock market since 2019
898 employees
$2.6B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $31 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 31%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
62%Products
Products 62%Service Revenue 38%
62% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 111% a year over the last 4 years. Red columns mark years that ended in a loss.

$30.3M
2021
$93.5M
2022
$241.6M
2023
$441.5M
2024
$605.5M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
91
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
23
very weak

Clearly below the class average.

VALUATION
72
strong

Clearly above the class average — a step short of the very top.

GROWTH
100
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
21
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit on each sale8/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 57% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat profit margin

The net profit margin is 31% — that slice of every sale is the company’s cushion in hard quarters.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 86% a year on average.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 23 buys and 21 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 21/100. For a turnaround signal, the stock first needs to close the gap with the market.

2
THE RISKS · 2/2
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, TMDX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: TMDX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 23, 2026 · stockexpertai.com · Stock Film